baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Goldman Sachs Discount Zert BAYN .../ DE000GQ590F4 /

1/9/2025 9:59:33 AM	Chg.-	Bid10:00:26 PM	Ask10:00:26 PM	Underlying	Strike price	Expiration date	Option type
19.72EUR	-	- Bid Size: -	- Ask Size: -	BAYER AG NA O.N.	- -	3/25/2025	Call

TeleTrader 11/12/2024 Bayer dips 12%, hits 20-year low after earnings report

TeleTrader 11/12/2024 Bayer's sales in Q3 down 3.6% to €9.9 billion

TeleTrader 8/16/2024 Bayer jumps 10% after Roundup court win

GlobeNewswire 8/2/2024 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...

GlobeNewswire 7/11/2024 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...

GlobeNewswire 6/25/2024 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial

GlobeNewswire 5/30/2024 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines

GlobeNewswire 5/30/2024 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...

GlobeNewswire 5/29/2024 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 5/28/2024 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement

TeleTrader 5/14/2024 Bayer's sales in Q1 at €13.7 billion, down 4.3%

GlobeNewswire 5/2/2024 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...

GlobeNewswire 4/18/2024 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...

GlobeNewswire 4/16/2024 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...

GlobeNewswire 4/11/2024 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...

GlobeNewswire 4/9/2024 AskBio Names Mansuo Shannon Chief Scientific Officer

GlobeNewswire 3/25/2024 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...

GlobeNewswire 3/14/2024 Bayer and Aignostics to collaborate on next generation precision oncology

GlobeNewswire 3/6/2024 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...

TeleTrader 3/5/2024 Bayer's Q4 sales at €11.9 billion

GlobeNewswire 3/4/2024 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

TeleTrader 3/4/2024 Earnings preview: Bayer, Broadcom among those in calendar

GlobeNewswire 2/15/2024 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust

GlobeNewswire 2/13/2024 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...

GlobeNewswire 2/13/2024 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure

Goldman Sachs Discount Zert BAYN .../ DE000GQ590F4 /

If you wish to receive reply to your feedback, please provide your email address.